[ad_1]
HYDERABAD: In what is perhaps a first, a high-level delegation of the US drug regulator US Food & Drug Administration, led by its commissioner Dr Robert M Califf visited the manufacturing facilities of Hyderabad-based active pharmaceutical ingredients (API) manufacturer Divi’s Laboratories on Tuesday.
The other members of the team included USFDA’s India Country director Dr Sarah McMullen visited the company’s manufacturing facility in Choutuppal on Hyderabad’s outskirts in Telangana.
Divi’s Laboratories said it showcased its large-scale world-class production facilities, advanced automated manufacturing capabilities, commitment to innovation, and its crucial role in investing in new technologies to ensure a consistent supply of high-quality APIs.
The USFDA delegation also interacted with the top management of Divi’s Laboratories, which supplies APIs to over 100 countries.
The visit of the US drug regulator’s delegation’s covered a wide range of topics, reflecting the dynamic landscape of the API industry, the integration of new technologies, sustainable practices in chemistry, raising manufacturing standards, and ensuring the availability of APIs.
“We are proud to participate in this important visit to share our role as a reliable API manufacturer that can deliver large quantities in a relatively short time,” said Dr Kiran S Divi, CEO, Divi’s Laboratories Limited. “We look forward to continuing to engage and be a part of addressing critical issues that affect the worldwide pharmaceutical industry,” he added.
The other members of the team included USFDA’s India Country director Dr Sarah McMullen visited the company’s manufacturing facility in Choutuppal on Hyderabad’s outskirts in Telangana.
Divi’s Laboratories said it showcased its large-scale world-class production facilities, advanced automated manufacturing capabilities, commitment to innovation, and its crucial role in investing in new technologies to ensure a consistent supply of high-quality APIs.
The USFDA delegation also interacted with the top management of Divi’s Laboratories, which supplies APIs to over 100 countries.
The visit of the US drug regulator’s delegation’s covered a wide range of topics, reflecting the dynamic landscape of the API industry, the integration of new technologies, sustainable practices in chemistry, raising manufacturing standards, and ensuring the availability of APIs.
“We are proud to participate in this important visit to share our role as a reliable API manufacturer that can deliver large quantities in a relatively short time,” said Dr Kiran S Divi, CEO, Divi’s Laboratories Limited. “We look forward to continuing to engage and be a part of addressing critical issues that affect the worldwide pharmaceutical industry,” he added.
[ad_2]
Source link
